Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I)

2005 ◽  
Vol 17 (1) ◽  
pp. 70-78 ◽  
Author(s):  
Gregory M Pastores ◽  
Patrick A Meere
2008 ◽  
Vol 23 (2) ◽  
pp. 108-111 ◽  
Author(s):  
Attila Nemes ◽  
Remco G. M. Timmermans ◽  
J. H. P. Wilson ◽  
Osama I. I. Soliman ◽  
Boudewijn J. Krenning ◽  
...  

Cells ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 129
Author(s):  
Concetta De Filippis ◽  
Barbara Napoli ◽  
Laura Rigon ◽  
Giulia Guarato ◽  
Reinhard Bauer ◽  
...  

Deficit of the IDUA (α-L-iduronidase) enzyme causes the lysosomal storage disorder mucopolysaccharidosis type I (MPS I), a rare pediatric neurometabolic disease, due to pathological variants in the IDUA gene and is characterized by the accumulation of the undegraded mucopolysaccharides heparan sulfate and dermatan sulfate into lysosomes, with secondary cellular consequences that are still mostly unclarified. Here, we report a new fruit fly RNAi-mediated knockdown model of a IDUA homolog (D-idua) displaying a phenotype mimicking some typical molecular features of Lysosomal Storage Disorders (LSD). In this study, we showed that D-idua is a vital gene in Drosophila and that ubiquitous reduction of its expression leads to lethality during the pupal stage, when the precise degradation/synthesis of macromolecules, together with a functional autophagic pathway, are indispensable for the correct development to the adult stage. Tissue-specific analysis of the D-idua model showed an increase in the number and size of lysosomes in the brain and muscle. Moreover, the incorrect acidification of lysosomes led to dysfunctional lysosome-autophagosome fusion and the consequent block of autophagy flux. A concomitant metabolic drift of glycolysis and lipogenesis pathways was observed. After starvation, D-idua larvae showed a quite complete rescue of both autophagy/lysosome phenotypes and metabolic alterations. Metabolism and autophagy are strictly interconnected vital processes that contribute to maintain homeostatic control of energy balance, and little is known about this regulation in LSDs. Our results provide new starting points for future investigations on the disease’s pathogenic mechanisms and possible pharmacological manipulations.


PLoS ONE ◽  
2019 ◽  
Vol 14 (5) ◽  
pp. e0217780 ◽  
Author(s):  
Andrea N. Crivaro ◽  
Juan M. Mucci ◽  
Constanza M. Bondar ◽  
Maximiliano E. Ormazabal ◽  
Romina Ceci ◽  
...  

2019 ◽  
Vol 5 (2) ◽  
pp. 24 ◽  
Author(s):  
Alberto B. Burlina ◽  
Giulia Polo ◽  
Laura Rubert ◽  
Daniela Gueraldi ◽  
Chiara Cazzorla ◽  
...  

The increasing availability of treatments and the importance of early intervention have stimulated interest in newborn screening for lysosomal storage diseases. Since 2015, 112,446 newborns in North Eastern Italy have been screened for four lysosomal disorders—mucopolysaccharidosis type I and Pompe, Fabry and Gaucher diseases—using a multiplexed tandem mass spectrometry (MS/MS) assay system. We recalled 138 neonates (0.12%) for collection of a second dried blood spot. Low activity was confirmed in 62 (0.06%), who underwent confirmatory testing. Twenty-five neonates (0.02%) were true positive: eight with Pompe disease; seven with Gaucher disease; eight with Fabry disease; and two with Mucopolysaccharidosis type I. The combined incidence of the four disorders was 1 in 4497 births. Except for Pompe disease, a second-tier test was implemented. We conclude that newborn screening for multiple lysosomal storage diseases combined with a second-tier test can largely eliminate false-positives and achieve rapid diagnosis.


Sign in / Sign up

Export Citation Format

Share Document